Though informal and unblinded, the study concluded that stem cell therapy may provide clinical benefit and be a low-risk treatment option for cats with chronic CKD.
POWAY, Calif. (PRWEB) September 11, 2018
Leading regenerative veterinary medicine company, VetStem Biopharma, will be exhibiting at the American Association of Feline Practitioners Conference (AAFP) later this month. The company’s CEO and founder, Dr. Robert Harman, will be presenting data on adipose-derived stem cell therapy for the treatment of chronic kidney disease in felines at a poster session on Saturday, September 29th. The conference is being held in Charlotte, North Carolina September 27-30, 2018.
At the poster session, Dr. Harman will be presenting and answering questions regarding outcome data collected on 40 clinical cases of chronic kidney disease (CKD) in cats that were treated with adipose-derived stem cell therapy. The authors hypothesized that stem cell therapy could improve the clinical course of CKD. Though informal and unblinded, the study concluded that stem cell therapy may provide clinical benefit and be a low-risk treatment option for cats with chronic CKD.
Additional controlled studies are necessary to further evaluate the benefit of adipose-derived stem cell therapy in CKD however these initial results are promising as recent reviews suggest that CKD may be the number one cause of mortality in older felines. While VetStem’s autologous (patient-derived) stem cell service is available to veterinarians in the United States and Canada, the company has plans to work with the FDA to develop an off-the-shelf donor-derived stem cell product for use in feline disease therapy. Currently, the company has three Investigational New Animal Drug applications filed with the FDA.
As the first company to provide adipose-derived stem cell services to veterinarians across the United States and Canada, VetStem Biopharma is considered a leader in the industry of regenerative veterinary medicine. Over 14,000 animals have been treated utilizing the company’s autologous stem cell service. Dr. Harman has been a trailblazer in the field of regenerative medicine for over a decade and presents at both human and animal medical conferences around the world. He most recently spoke in Sacramento at the 2018 North American Veterinary Regenerative Medicine Association Conference. He applies his biotechnology and veterinary experience in the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. Dr. Harman has also authored 14 peer-reviewed articles and book chapters.
About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 16 years and 14,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.